[9] This prompted us to evaluate if single CD24 expression affects prognosis in adjuvant tamoxifen-treated breast cancer patients, instead of performing further analysis of the relationship between CD44+/CD24- and clinical outcome. The gene discussed is CD44; the disease is breast cancer.